JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB76305

Anti-Apolipoprotein CIII antibody [EP1372Y]

4

(4 Reviews)

|

(6 Publications)

Rabbit Recombinant Monoclonal Apolipoprotein CIII antibody. Suitable for WB and reacts with Human samples. Cited in 6 publications.

View Alternative Names

Apolipoprotein C-III, Apo-CIII, ApoC-III, Apolipoprotein C3, APOC3

2 Images
Western blot - Anti-Apolipoprotein CIII antibody [EP1372Y] (AB76305)
  • WB

Unknown

Western blot - Anti-Apolipoprotein CIII antibody [EP1372Y] (AB76305)

All lanes:

Western blot - Anti-Apolipoprotein CIII antibody [EP1372Y] (ab76305) at 1/2000 dilution

All lanes:

Human liver tissue lysate at 10 µg

Secondary

All lanes:

HRP labelled goat anti-rabbit at 1/2000 dilution

Predicted band size: 11 kDa,61 kDa

Observed band size: 11 kDa,61 kDa

false

Western blot - Anti-Apolipoprotein CIII antibody [EP1372Y] (AB76305)
  • WB

Supplier Data

Western blot - Anti-Apolipoprotein CIII antibody [EP1372Y] (AB76305)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

Please note this image was obtained using a purified batch. The current WB image of the Human liver is obtained using an unpurified batch.

All lanes:

Western blot - Anti-Apolipoprotein CIII antibody [EP1372Y] (ab76305) at 10000 kDa

All lanes:

Human plasma lysate at 15 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG. at 1/20000 dilution

Predicted band size: 11 kDa

Observed band size: 11 kDa

false

Exposure time: 3s

  • Carrier free

    Anti-Apolipoprotein CIII antibody [EP1372Y] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EP1372Y

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Alternative Products

Primary Antibodies

AB21032

Anti-Apolipoprotein CIII antibody

Western blot - Anti-Apolipoprotein CIII antibody (AB21032)

  • 0
  • 0
Primary Antibodies

AB108205

Anti-Apolipoprotein CIII antibody [EPR1371(2)]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Apolipoprotein CIII antibody [EPR1371(2)] (AB108205)

  • 0
  • 0

Complementary Products

Assay Kits

AB65336

Triglyceride Assay Kit - Quantification

Biochemical assay - Triglyceride Assay Kit - Quantification (AB65336)

  • 4
  • 4
Primary Antibodies

AB52945

Anti-Apolipoprotein A I antibody [EP1368Y]

RabMAb|Recombinant

Flow Cytometry (Intracellular) - Anti-Apolipoprotein A I antibody [EP1368Y] (AB52945)

  • 4
  • 9
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB198288

Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (AB198288)

  • 0
  • 0
Primary Antibodies

AB139401

Anti-Apolipoprotein B antibody [EPR2914]

RabMAb|Recombinant

Western blot - Anti-Apolipoprotein B antibody [EPR2914] (AB139401)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/2000 - 1/10000", "WB-species-notes": "<p></p>" } } }
style
left-column

Product details

The production method for this product has been changed from hybridoma to recombinant on 18th June 2024.

Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Storage information
Stable for 12 months at -20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Apolipoprotein CIII also known as Apo C-III or ApoC3 is an apolipoprotein with a molecular mass of approximately 8.8 kDa. It is synthesized in the liver and intestine and circulates in the bloodstream primarily as part of very low-density lipoproteins (VLDL) and high-density lipoproteins (HDL). Its main role involves the regulation of lipid metabolism particularly in relation to triglyceride-rich particles. Apo C-III serves as an inhibitor of lipoprotein lipase an enzyme essential for the hydrolysis of triglycerides into free fatty acids.
Biological function summary

Apolipoprotein CIII plays a pivotal role in lipid and lipoprotein metabolism. It is not part of a large protein complex but interacts with lipoproteins as a modulatory protein. Apo C-III affects triglyceride metabolism by delaying the clearance of VLDL and enhancing hepatic triglyceride secretion. Additionally it modulates the uptake of lipoprotein remnants by liver receptors thereby influencing the plasma levels of triglycerides and cholesterol.

Pathways

Apolipoprotein CIII is involved in the regulation of lipid metabolic pathways. It plays a role in the lipoprotein assembly pathway and the triglyceride biosynthetic process. This protein impacts the interaction between lipoprotein lipase and its substrates hindering enzyme activity which leads to elevated plasma triglyceride levels. It relates closely to other apolipoproteins such as apolipoprotein E which also participates in lipid transport and metabolism although with distinct functions and regulatory mechanisms.

Apolipoprotein CIII is implicated in conditions like hypertriglyceridemia and cardiovascular disease. Elevated levels of Apo C-III contribute to high triglyceride levels promoting atherosclerosis development due to the retention of triglyceride-rich lipoproteins in the bloodstream. This association links it to cardiovascular disease risk where its role contrasts with proteins like apolipoprotein AI which is mainly involved in protective effects via HDL metabolism. Understanding the modulation of Apo C-III levels offers potential therapeutic avenues for managing these lipid-related disorders.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma (PubMed : 18201179, PubMed : 22510806). Plays a multifaceted role in triglyceride homeostasis (PubMed : 18201179, PubMed : 22510806). Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs) (PubMed : 18201179, PubMed : 22510806). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors (PubMed : 18201179, PubMed : 22510806). Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners (PubMed : 18408013).
See full target information Apolipoprotein C-III
style
left-column

Publications (6)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 14:4007 PubMed37414857

2023

Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for their function.

Applications

Unspecified application

Species

Unspecified reactive species

Kai Liu,Ralf Nilsson,Elisa Lázaro-Ibáñez,Hanna Duàn,Tasso Miliotis,Marie Strimfors,Michael Lerche,Ana Rita Salgado Ribeiro,Johan Ulander,Daniel Lindén,Anna Salvati,Alan Sabirsh

International journal of molecular medicine 45:1409-1416 PubMed32323743

2020

Proteomics analysis of potential serum biomarkers for insulin resistance in patients with polycystic ovary syndrome.

Applications

Unspecified application

Species

Unspecified reactive species

Li Li,Jing Zhang,Jing Zeng,Biling Liao,Xiuhong Peng,Tiantian Li,Jieming Li,Qiuxiao Tan,Xiaofang Li,Ying Yang,Zhijing Chen,Zhijiang Liang

Virology 524:1-9 PubMed30130702

2018

Characterization of apolipoprotein C1 in hepatitis C virus infection and morphogenesis.

Applications

Unspecified application

Species

Unspecified reactive species

Han Zhang,Luhua Qiao,Guangxiang Luo

International journal of molecular medicine 41:61-68 PubMed29115584

2017

Apolipoprotein C-III in the high-density lipoprotein proteome of cerebral lacunar infarction patients impairs its anti-inflammatory function.

Applications

Unspecified application

Species

Unspecified reactive species

Pu Lv,Mingming Zhao,Yuanyuan Liu,Haiqiang Jin,Wei Cui,Chenghe Fan,Yuming Teng,Lemin Zheng,Yining Huang

EBioMedicine 16:204-211 PubMed28111237

2017

Human Neutrophil Peptide 1 Limits Hypercholesterolemia-induced Atherosclerosis by Increasing Hepatic LDL Clearance.

Applications

Unspecified application

Species

Unspecified reactive species

Nicole Paulin,Yvonne Döring,Sander Kooijman,Xavier Blanchet,Joana R Viola,Renske de Jong,Manuela Mandl,Jeffrey Hendrikse,Maximilian Schiener,Philipp von Hundelshausen,Anja Vogt,Christian Weber,Khalil Bdeir,Susanna M Hofmann,Patrick C N Rensen,Maik Drechsler,Oliver Soehnlein

Journal of lipid research 52:1265-71 PubMed21371998

2011

Development of a sensitive ELISA to quantify apolipoprotein CIII in nonhuman primate serum.

Applications

Unspecified application

Species

Unspecified reactive species

Yuxin Wang,Zhili Song,Janice D Wagner,Catherine Pachuk,Romesh R Subramanian
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com